Clinical Trials Directory

Trials / Completed

CompletedNCT01520233

Gene Expression in Predicting Outcome in Samples From Patients With High-Risk Neuroblastoma

Genome Based Outcome Prediction in High Risk Neuroblastoma

Status
Completed
Phase
Study type
Observational
Enrollment
100 (actual)
Sponsor
Children's Oncology Group · Network
Sex
All
Age
Healthy volunteers
Not accepted

Summary

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in RNA and predict how patients will respond to treatment. It may also help doctors find better ways to treat cancer. PURPOSE: This research trial studies gene expression in predicting outcomes in samples from patients with high-risk neuroblastoma.

Detailed description

OBJECTIVES: * To test the correlation of a previously published microarray gene expression signature with the gene expression obtained with the nCounter™ Analysis System using RNA isolated from formalin-fixed, paraffin-embedded (FFPE), high-risk neuroblastoma samples. * To construct, test, and validate a novel robust classifier that can be readily integrated into the clinic. OUTLINE: This is a multicenter study. RNA samples extracted from paraffin-embedded tissue are analyzed for gene signature expression levels by nCounter™ Analysis System and correlated with published microarray expression data. Results are then used to develop a refined gene-expression-profile classifier of ultra high-risk neuroblastoma.

Conditions

Interventions

TypeNameDescription
GENETICRNA analysis
GENETICgene expression analysis
OTHERlaboratory biomarker analysis

Timeline

Start date
2012-01-01
Primary completion
2016-05-01
Completion
2016-05-01
First posted
2012-01-27
Last updated
2016-05-17

Source: ClinicalTrials.gov record NCT01520233. Inclusion in this directory is not an endorsement.